Annual report pursuant to Section 13 and 15(d)

SELECTED QUARTERLY FINANCIAL DATA

v3.19.3.a.u2
SELECTED QUARTERLY FINANCIAL DATA
12 Months Ended
Dec. 31, 2019
SELECTED QUARTERLY FINANCIAL DATA  
SELECTED QUARTERLY FINANCIAL DATA

14. SELECTED QUARTERLY FINANCIAL DATA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2019

 

Year Ended December 31, 2018

 

 

 

Q1

 

Q2

 

Q3

 

Q4

 

Q1

 

Q2

 

Q3

 

Q4

 

 

 

(unaudited, in thousands, except per share amounts)

 

Revenue

    

$

12,624

    

$

10,407

    

$

20,857

    

$

15,400

    

$

 —

    

$

1,787

    

$

4,865

    

$

37,857

 

Gross profit*

    

$

7,947

 

$

9,862

 

$

11,406

 

$

13,651

 

$

 —

 

$

1,757

 

$

4,796

 

$

7,107

 

Net loss

 

$

(17,598)

 

$

(20,606)

 

$

(11,490)

 

$

(17,200)

 

$

(24,385)

 

$

(25,557)

 

$

(23,766)

 

$

3,228

 

Net income (loss) per share, basic and diluted:

 

$

(0.11)

 

$

(0.12)

 

$

(0.07)

 

$

(0.10)

 

$

(0.17)

 

$

(0.16)

 

$

(0.14)

 

$

0.02

 

Weighted average shares used in computing net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

167,173

 

 

167,191

 

 

167,609

 

 

167,619

 

 

147,114

 

 

161,577

 

 

166,464

 

 

166,680

 

Diluted

 

 

167,173

 

 

167,191

 

 

167,609

 

 

167,745

 

 

147,114

 

 

161,577

 

 

166,464

 

 

167,617

 


*Gross profit is computed as Net product sales less Cost of product sales. Prior to the FDA approval, manufacturing and related costs were charged to research and development expense. Therefore, these costs were not capitalized and as a result, are not fully reflected in the costs of sales during the periods disclosed above.